Oncology Biosimilars Market: By Drug Type (Monoclonal Antibody, Immunomodulators, G-CSF, Hematopoietic Agents, and Others) By Cancer Type (Lung Cancer, Colorectal Cancer, Cervical Cancer, Breast Cancer, and Others), and Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Oncology Biosimilars Market size was valued at USD 3.5 billion in 2022 and is poised to grow at a significant CAGR of 29.0% from 2023-2029. According to the World Health Organization (WHO), cancer is one of the second most important causes of death worldwide. According to WHO figures, 9.6 million people died from cancer in 2018. These figures emphasize the importance of reducing cancer-related fatalities. The growth of the oncology biosimilars market has been fueled by an increase in cancer cases such as lung cancer and breast cancer, a vulnerable aging population, and increasing research and development activities by multiple pharmaceutical companies. The Biosimilars are biological medications demonstrated to be highly similar to the original drug in terms of potency, safety, and purity. Oncology biosimilars are used to treat a variety of cancers and symptoms as therapeutic, diagnostic, or preventive agents. The oncology biosimilars are the first choice for many cancer patients, resulting in a faster growth rate. Pharmaceutical companies are capitalizing on the expanding biosimilar market's growth potential by investing in their research and development (R&D) operations to support the development and production of new biosimilars. For example, Coherus and Junshi Biosciences announced a partnership in February 2021 in which Coherus would in-license toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus intends to use cash from its commercial biosimilar company to develop a top immuno-oncology franchise. In addition, Biocon, India's largest biotechnology business, invested in Pfizer Healthcare's assets to establish an R&D facility to accelerate biosimilar development. Moreover, FDA has approved Oncology biosimilars in large numbers, a trend that is expected to continue in the future years. The FDA approved two significant biosimilars: filgrastim-sndz (Zarxio) and bevacizumab-awwb (Mvasi). The impact of the increasing approval rate on market maturity will be intriguing to watch. Approaching patent expirations of branded biologics and increased research and development (R&D) activity by biosimilar manufacturers are some of the critical growth-inducing factors for the market.

Oncology Biosimilars Market Key Developments:
  • In December 2020, Amgen received United States Food and Drug Administration (USFDA) approval for RIABNI (rituximab-arrx). RIABNI (rituximab-arrx) is a biosimilar to rituximab used to treat adult patients suffering from non-Hodgkin lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, and microscopic polyangiitis (MPA).

Oncology Biosimilars Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Asia Pacific
Oncology Biosimilars Market Dynamics

According to the American Journal of Managed Care, biosimilars are cheaper than their parent/branded counterparts, and this saves money while giving patients access to highly effective medicines. Biosimilars have more affordable R&D expenses than originator biologics, and Biosimilars are less expensive since R&D expenses are reduced. Biosimilars with lower prices tend to drive down the costs of reference biologics due to price rivalry among manufacturers. Biosimilar medications' considerable cost-to-benefit ratio is predicted to increase their demand in the coming years. However, biosimilar development is a time-consuming and expensive procedure requiring significant financial inputs, technical capabilities, clinical trial knowledge, scientific standards, and quality control systems. The oncology biosimilars market is limited by a lack of understanding among primary care physicians (PCPs) and specialists about biosimilars.

Key Features of the Reports

  • The oncology biosimilars market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Oncology Biosimilars Market Segmentation

By Drug Type
  • Monoclonal Antibody
  • Immunomodulators
  • G-CSF
  • Hematopoietic Agents
  • Others
By Cancer Type
  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Breast Cancer
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The Oncology Biosimilars Market is projected to expand at a CAGR of 29.0% during the forecast period  

Bitcoin, Celltrion inc, Reddy's Laboratories Ltd, Intas Pharmaceuticals Ltd, STADA Arzneimittel AG

North America is the fastest-growing region for Oncology Biosimilars Market

  • Biocoin
  • Celltrion inc.
  • Reddy's Laboratories Ltd.
  • Intas Pharmaceuticals Ltd.
  • STADA Arzneimittel AG
  • Pfizer inc.
  • Apotex inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Amgen
  • Hospira